Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 1.00 |
| ▸ | MAOA | P21397 | 4/20 | 0.81 |
| ▸ | ACHE | P22303 | 1/20 | 0.71 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | MLLT1 | Q03111 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.52 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15875707 | 0.90 | MAOB (1.00) | MAOBMAOAACHELRRK2MLLT1 | |
| SCHEMBL15874997 | 0.83 | MAOB (1.00) | MAOBMAOAACHELRRK2MLLT1 | |
| SCHEMBL29510910 | 0.80 | NPC1 (0.78) | MAOBMAOAACHELRRK2MLLT1 | |
| SCHEMBL19662760 | 0.78 | NPC1 (0.64) | MAOBMAOAACHENPC1RAB9A | |
| SCHEMBL23559657 | 0.77 | CCNC (0.63) | MAOBMAOAACHELRRK2MLLT1 | |
| SCHEMBL30147566 | 0.77 | CCNC (0.63) | MAOBMAOAACHELRRK2MLLT1 | |
| SCHEMBL22445841 | 0.77 | LRRK2 (0.70) | MAOBMAOAACHELRRK2MLLT1 | |
| SCHEMBL15428978 | 0.76 | MAOB (0.61) | MAOBMAOAACHELRRK2MLLT1 | |
| SCHEMBL15887006 | 0.76 | MAOB (1.00) | MAOBMAOAMLLT1NPC1RAB9A | |
| SCHEMBL4410330 | 0.75 | MAOB (0.59) | MAOBMAOAACHELRRK2MLLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643930-B2 | Substituted indazole derivatives as in vitro MAO-B inhibitors | “NTZ LAB” LTD. (BG) | 2017-05-09 | — | — | US | claimed |
| EP-2964219-B1 | SUBSTITUTED INDAZOLE OR INDOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | NTZ LAB LTD (BG) | 2017-05-03 | — | — | EP | claimed |
| EP-2964219-A1 | SUBSTITUTED INDAZOLE OR INDOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ Lab" Ltd. (BG) | 2016-01-13 | — | — | EP | claimed |
| US-20150353504-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ LAB" LTD. (BG) | 2015-12-10 | — | — | US | claimed |
| WO-2014107771-A1 | SUBSTITUTED INDAZOLE OR INDOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ LAB" LTD. (BG) | 2014-07-17 | — | — | WO | claimed |
| US-9643930-B2 | Substituted indazole derivatives as in vitro MAO-B inhibitors | “NTZ LAB” LTD. (BG) | 2017-05-09 | — | — | US | disclosed |
| US-9643930-B2 | Substituted indazole derivatives as in vitro MAO-B inhibitors | “NTZ LAB” LTD. (BG) | 2017-05-09 | — | — | US | disclosed |
| US-9643930-B2 | Substituted indazole derivatives as in vitro MAO-B inhibitors | “NTZ LAB” LTD. (BG) | 2017-05-09 | — | — | US | disclosed |
| EP-2964219-B1 | SUBSTITUTED INDAZOLE OR INDOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | NTZ LAB LTD (BG) | 2017-05-03 | — | — | EP | disclosed |
| EP-2964219-B1 | SUBSTITUTED INDAZOLE OR INDOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | NTZ LAB LTD (BG) | 2017-05-03 | — | — | EP | disclosed |
| EP-2964219-A1 | SUBSTITUTED INDAZOLE OR INDOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ Lab" Ltd. (BG) | 2016-01-13 | — | — | EP | disclosed |
| US-20150353504-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ LAB" LTD. (BG) | 2015-12-10 | — | — | US | disclosed |
| US-20150353504-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ LAB" LTD. (BG) | 2015-12-10 | — | — | US | disclosed |
| US-20150353504-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ LAB" LTD. (BG) | 2015-12-10 | — | — | US | disclosed |
| WO-2014107771-A1 | SUBSTITUTED INDAZOLE OR INDOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ LAB" LTD. (BG) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014107771-A1 | SUBSTITUTED INDAZOLE OR INDOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | "NTZ LAB" LTD. (BG) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353504-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AS IN VITRO MAO-B INHIBITORS | MAOB, MAOA, HNMT | MAOB 1/4885MAOA 2/4885ACHE 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.